Skip to content

A Dose-response Study of Lidocaine and Etomidate

Can Intravenous Lidocaine Decrease the Minimal Inducing Dose of Etomidate?: A Randomized Placebo-controlled Dose-response Study.

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01916642
Enrollment
100
Registered
2013-08-05
Start date
2013-04-30
Completion date
2013-07-31
Last updated
2013-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Etomidate Overdose of Undetermined Intent

Keywords

iv lidocaine, inducing dose, etomidate, dose response

Brief summary

IV lidocaine administration can reduce the minimal amount of Etomidate and time for induction of anesthesia.

Detailed description

The study was carried out in West China Hospital of Sichuan University, Chengdu, China. All the patients were informed in detail about the procedure and the medications they are going to get. Patients are well informed about the beneficial and possible hazards of the medicines and procedure. Patients are also informed that they can withdraw from the study at any time if they find it uncomfortable or harmful for them. Patients' written informed consent was obtained and registered for the permission from the Hospital's Ethics Board.

Interventions

DRUGLidocaine 1mg/kg

The total dosage of Etomidate needed for induction of anesthesia is recorded at last.

DRUGLidocaine 1.5mg/kg

same as other

DRUGLidocaine 2mg/kg

same as other

DRUGLidocaine 2.5mg/kg

same as other

Sponsors

West China Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

1. Patients scheduled for Elective Surgery, 2. age limit within 18-70 years, 3. American Society of Anaesthesiologists physical status classification I-II

Exclusion criteria

1. Adrenal Cortex disorder, 2. Neurologic disease, 3. Psychiatric disorders, 4. Allergic to Local anesthetic drugs, 5. Patients who have received sedatives,analgesics or opioids within the previous 24 hrs.

Design outcomes

Primary

MeasureTime frame
changes in blood pressure and heart rate.6 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026